Compare Linde PLC (LIN) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs Oscar Health Inc — how do they compare? Linde PLC trades at $484.71 (market cap $222.05B), while Oscar Health Inc trades at $33.4 (market cap $10.22B). The key difference: Linde PLC is far larger — about 21.7× Oscar Health Inc's market cap, and Linde PLC pays a 1.33% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Linde PLC for 88 Days and Oscar Health Inc for 15 Days on average.
| LIN | OSCR | |
|---|---|---|
Market Cap | $222.05B | $10.22B |
Volume | 2,116,440 | 4,123,394 |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $33.81 |
52-Week Low | $389.38 | $10.85 |
Typical Hold Time | 88 Days | 15 Days |
Enterprise Value | $245.17B | $6.57B |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LIN trades at $483.98, down 1.22% on the day, with a bullish technical signal from moving averages and strong support near $482. The company reported record Q2 2026 EPS of $4.50, beating estimates, and maintains robust profitability with a 20.43% net income margin. Revenue growth is steady, projected at $35.4B for 2026, while valuation multiples like the 31.08 P/E reflect premium pricing. Analyst sentiment is overwhelmingly positive, with 89.66% buy ratings and a $557.10 consensus price target, citing LIN's role in AI chip supply chains.
The outlook for LIN is favorable, driven by earnings beats, a record $8.1B project backlog, and strategic positioning in high-growth sectors like electronics. Key risks include elevated valuation requiring sustained growth, rising debt-to-asset ratios, and margin pressures from increased capital expenditure. Investors should weigh the company's strong execution against potential sector-wide competition and macroeconomic headwinds affecting industrial demand.
OSCR trades at $33.41, up 1.52% today, with a bullish technical signal and strong recent earnings beats in Q1 and Q2 2026. The stock shows robust revenue growth, with 2026 revenue projected at $15.3B and a return to profitability. Analyst sentiment is mixed but leans positive, with a consensus price target of $34.00. Recent news highlights market share gains and raised 2026 guidance, though the stock faces tests from rising medical costs.
The outlook is cautiously optimistic, driven by scalable growth in the ACA market and margin expansion opportunities. Key risks include medical cost pressures and competitive threats. Upside potential exists if the company executes on its 2029 EPS target of $4+, but investors should monitor profitability sustainability amid cost headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
